U3 1402

Drug Profile

U3 1402

Alternative Names: U3-1402; U3-1402a

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer

Most Recent Events

  • 01 Nov 2016 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Japan (IV) (NCT02980341)
  • 11 Oct 2016 Preclinical trials in Solid tumours in Japan (IV) before October 2016
  • 11 Oct 2016 Daiichi Sankyo plans a first-in-human phase I/II trial for Breast cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Japan (IV) (NCT02980341; JapicCTI-163401)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top